Last reviewed · How we verify

NCT04147962: LACRYSTIM

Intense Pulsed Light in Meibomian Gland Dysfunctions

Completed Last updated 13 May 2022
What this trial tests

trial testing intense pulsed light (usual practice) in Dry Eye Syndromes in 45 participants. Completed in 1 June 2020.

Timeline
25 October 2019
Primary endpoint
1 June 2020
1 June 2020

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
StatusCompleted
Study typeOBSERVATIONAL
Enrollment45
Start date25 October 2019
Primary completion1 June 2020
Estimated completion1 June 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Dry Eye Syndromes or Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dry eye disease (DED) is an extremely common disease whose meibomian gland dysfunction is the main etiology. Polychromatic intense pulsed light (IPL) is a promising new therapeutic alternative but few clinical data have been published. A new IPL device has recently been marketed: LACRYSTIM (QUANTEL, France). The investigators have been using it in our clinical practice since June 2019. The investigators present a retrospective study on our first clinical results.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A retrospective study of the efficacy of intense pulsed light delivered by the Lacrystim® for meibomian gland dysfunction therapy.
    Trone MC, Garcin T, Ollier E, Thuret G, et al · · 2022 · cited 7× · PMID 35933379 · DOI 10.1186/s12886-022-02531-7

Verify or expand the search:

Other recruiting trials for Dry Eye Syndromes

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04147962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing